Our Development Pipeline
We are currently focussing our research and development efforts on a rare orphan skin fragility disorder known as RDEB, for which there are currently no treatments available. Leveraging on our polyfunctional cationic polymer gene editing platform delivery system we are presently expanding our pipeline to encompass additional therapeutic targets including Cystic Fibrosis and Inherited Corneal Disorders.
Pipeline Expansion
Following on from our initial target BrB101 for Dystrophic EB, we are currently exploring additional therapeutic targets for other inherited genetic disorders through our R&D platform. BrB102 and BrB103 designed to target Cystic Fibrosis and inherited corneal disorders respectively are undergoing discovery phase at Branca Bunús at present.

Find Us
Branca Bunús Ltd
Nova UCD
Belfield Innovation Campus
University College Dublin
Belfield, Dublin 4
D04 V1W8
Ireland